Moneycontrol PRO

business

Margins may be hit on one-off items in EBITDA: Sun Pharma

Uday Baldota, VP- investor relations, Sun Pharma tells CNBC-TV18 that apart from the drug Taro‘s stellar contribution, other business segments also performed well

first published: May 30, 2012 05:04 pm

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347